New York legislation · 2025-2026 General Assembly
New York A9156: Prohibits the sale of 7-hydroxymitragynine products
Status: In committee, June 3, 2026
Prohibits the sale of products that contain 7-hydroxymitragynine at a level that exceeds 2% of total alkaloids or one milligram per serving; establishes fines for the sale of such products.
What the bill says
An act to amend the general business law, in relation to prohibiting the sale of 7-hydroxymitragynine products.
From the amended text, May 8, 2026:
AN ACT to amend the general business law, in relation to prohibiting the sale of 7-hydroxymitragynine products THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS: Section 1. The general business law is amended by adding a new section 392-l to read as follows: § 392-L. SALE OF 7-HYDROXYMITRAGYNINE PRODUCTS. 1. FOR PURPOSES OF THIS SECTION, THE TERM "7-HYDROXYMITRAGYNINE PRODUCTS" SHALL MEAN ANY SUBSTANCE, MATERIAL, MIXTURE, COMPOUND, PREPARATION, EXTRACT, OR FINISHED GOODS THAT CONTAINS 7-HYDROXYMITRAGYNINE AT A LEVEL THAT EXCEEDS TWO PERCENT OF TOTAL ALKALOIDS OR ONE MILLIGRAM PER SERVING. 2. THE PROVISIONS OF THIS SECTION SHALL APPLY TO THE SALE, OFFER FOR SALE, DELIVERY, OR DISTRIBUTION OF ALL 7-HYDROXYMITRAGYNINE PRODUCTS. 3. NO CORPORATION, PARTNERSHIP, LIMITED LIABILITY COMPANY, FIRM, ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER 7-HYDROXYMITRAGYNINE PRODUCTS. 4. ANY CORPORATION, PARTNERSHIP, LIMITED LIABILITY COMPANY, FIRM, ONLINE PLATFORM, OR OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS STATE THAT VIOLATES THE PROVISIONS OF THIS SECTION BY KNOWINGLY SELLING, OFFERING FOR SALE, OR DELIVERING 7-HYDROXYMITRAGYNINE PRODUCTS SHALL BE SUBJECT TO A CIVIL PENALTY OF NOT MORE THAN FIVE HUNDRED DOLLARS FOR A FIRST VIOLATION, AND ONE THOUSAND DOLLARS FOR EACH SUBSEQUENT VIOLATION, EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets …
Sponsors
- Phillip Steck (D, 110) · primary sponsor
- Mary Walsh (R, 112)
- Judy Griffin (D, 21)
- Andrew Hevesi (D, 28)
- Marianne Buttenschon (D, 119)
- Jo Simon (D, 52)
- Deborah Glick (D, 66)
- Alicia Hyndman (D, 29)
- Edward Ra (R, 19)
- John McDonald (D, 108)
- Michael Novakhov (R, 45)
- Matthew Simpson (R, 114)
Latest actions
- : SUBSTITUTED BY S8925A
- : ORDERED TO THIRD READING RULES CAL.408
- : RULES REPORT CAL.408
- : REPORTED
- : REPORTED REFERRED TO RULES
- : REPORTED REFERRED TO WAYS AND MEANS
- : REPORTED REFERRED TO CODES
- : PRINT NUMBER 9156B
- : AMEND AND RECOMMIT TO CONSUMER AFFAIRS AND PROTECTION
- : PRINT NUMBER 9156A
Votes
- Assembly Ways And Means Committee: Favorable refer to committee Rules (June 3, 2026): 32 yea, 0 nay, passed
- Assembly Rules Committee: Favorable (June 3, 2026): 29 yea, 0 nay, passed
- Assembly Codes Committee: Favorable refer to committee Ways and Means (May 28, 2026): 18 yea, 0 nay, passed
- Assembly Consumer Affairs And Protection Committee: Favorable refer to committee Codes (May 11, 2026): 12 yea, 0 nay, passed
Subjects: General Business Law
Common questions
- What is A9156?
- A9156 is a bill in the New York Legislature (2025-2026 General Assembly): Prohibits the sale of 7-hydroxymitragynine products.
- What does A9156 do?
- In its own words: An act to amend the general business law, in relation to prohibiting the sale of 7-hydroxymitragynine products.
- What is the status of A9156?
- In committee as of June 3, 2026. Latest action: SUBSTITUTED BY S8925A (June 3, 2026).
- Who sponsored A9156?
- Phillip Steck (D, 110), with 11 co-sponsors.
- Where is the official record for A9156?
- On the New York Legislature website: https://www.nysenate.gov/legislation/bills/2025/A9156
Source: official New York record. Tracked by Delilah, AI for legislation across all 50 states and Congress.